# Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets

> **NCT03803371** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ultracet Tablets
- **DRUG:** Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)

## Key facts

- **NCT ID:** NCT03803371
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03803371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03803371, "Bioequivalence Study of Tramadol Hydrochloride /Paracetamol Tablets Versus Ultracet Tablets". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03803371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*